移植物抗宿主病的预防进展

Progress in Prevention of Graft Versus Host Disease

造血干细胞移植(HSCT)现已被广泛应用于血液系统疾病的治疗,其中异基因造血干细胞移植(allo-HSCT)是目前治疗某些恶性血液病的唯一方法。然而,移植物抗宿主病(GVHD)的发生显著降低了移植后患者的生存率和生活质量,成为移植的最大障碍。近年来,随着对GVHD发生机制的深入研究和相关临床试验的开展,为allo-HSCT后GVHD的预防提供了更多的新型药物及联合用药选择,使得GVHD个体化预防诊治取得了较大的进展,同时脐带血(UCB)的进一步研究应用为HSCT患者带来了新的诊疗思路。本文将从预防GVHD的新型药物选择及最新研究进展进行相关综述。

Hematopoietic stem cell transplantation(HSCT)has been widely used in the treatment of hematological diseases.Currently,allo-HSCT is the only treatment for some hematologic malignancies.However,the occurrence of graft versus host disease(GVHD)has significantly reduced the survival rate and quality of recipients,and has become the biggest obstacle of transplantation.In recent years,with the in-depth study on the occurrence mechanism of GVHD and the development of relevant clinical trials,more new drugs and combined drug options are provided for the prevention of GVHD after allo-HSCT,which has made great progress in the individualized prevention and treatment of GVHD.Meanwhile,the further research and application of Umbilical Cord Blood(UCB)has brought new ideas for the diagnosis and treatment of patients with HSCT.This paper will review the selection of new drugs for the prevention of GVHD and the latest research progress.